Lack of therapeutic efficacy of an antibody to α<sub>4</sub>β<sub>7</sub> in SIVmac251-infected rhesus macaques.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31488689.
- Also identified by DOI 10.1126/science.aaw8562 and PMC identifier 6768629.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Sustained virologic control of human immunodeficiency virus type 1 (HIV-1) infection after discontinuation of antiretroviral therapy (ART) is a major goal of the HIV-1 cure field. A recent study reported that administration of an antibody against α<sub>4</sub>β<sub>7</sub> induced durable virologic control after ART discontinuation in 100% of rhesus macaques infected with an attenuated strain of simian immunodeficiency virus (SIV) containing a stop codon in <i>nef</i> We performed similar studies in 50 rhesus macaques infected with wild-type, pathogenic SIVmac251. In animals that initiated ART during either acute or chronic infection, anti-α<sub>4</sub>β<sub>7</sub> antibody infusion had no detectable effect on the viral reservoir or viral rebound after ART discontinuation. These data demonstrate that anti-α<sub>4</sub>β<sub>7</sub> antibody administration did not provide therapeutic efficacy in the model of pathogenic SIVmac251 infection of rhesus macaques.
Medical subject headings
- Antibodies, Monoclonal
- Antibodies, Viral
- Integrin alpha4
- Integrin beta Chains
- Simian Acquired Immunodeficiency Syndrome
- Simian Immunodeficiency Virus